Rebiotix Revenue and Competitors

Claim your profile

Location

$39.1M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Rebiotix's estimated annual revenue is currently $16.4M per year.(i)
  • Rebiotix received $8.5M in venture funding in September 2017.
  • Rebiotix's estimated revenue per employee is $155,000
  • Rebiotix's total funding is $39.1M.

Employee Data

  • Rebiotix has 106 Employees.(i)
  • Rebiotix grew their employee count by 10% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.5M74-9%N/AN/A
#2
$10.1M65-2%N/AN/A
#3
$16.3M1053%$20.5MN/A
#4
$16.4M10610%$39.1MN/A
#5
$10.1M6520%N/AN/A
#6
$20.6M133-1%N/AN/A
#7
$10.2M6669%N/AN/A
#8
$14.4M93-7%N/AN/A
#9
$3.3M21-22%N/AN/A
#10
$4M63-5%N/AN/A

Rebiotix Inc is a clinical-stage biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome. Our highly skilled and dynamic team is based out of Roseville, Minnesota. Please feel free to contact us through our website at www.rebiotix.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$39.1M

Total Funding

106

Number of Employees

$16.4M

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Rebiotix News

2022-04-17 - Microbiome-Based Enema Effective for Recurrent C. difficile

A stool-based enema composed of a broad variety of microbes (RBX2660, Rebiotix/Ferring) was up to 84% effective in reducing recurrent Clostridioides...

2022-03-22 - Could Microbiome-Based Therapeutics Fill the Unmet Need in ...

RBX2660 (Rebiotix); SER-109 (Seres Therapeutics); CP-101 (Finch Therapeutics); VE303 (Vedanta Biosciences); NTCD M3 (Destiny Pharmaceuticals)...

2022-03-22 - The year the regulators meet the microbiome

The project, comprising mixed bacterial consortia, was originated by Rebiotix, a US biotech that Ferring bought in 2018.

2019-09-08 - Rebiotix, Inc and Karolinska Institutet Expand Partnership to ...

ROSEVILLE, Minn.--(BUSINESS WIRE)-- Rebiotix Inc, a Ferring Pharmaceuticals company, announced today that their Chief Scientific Officer, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.4M1090%N/A
#2
$31.6M10917%N/A
#3
$18.1M111-4%N/A
#4
$26.5M11110%N/A
#5
$17M113414%N/A

Rebiotix Funding

DateAmountRoundLead InvestorsReference
2014-07-11$18.0MUndisclosedArticle
2014-08-05$25.0MBArticle
2017-09-08$8.5MUndisclosedArticle